Transforming PAH care in Italy: a clinical and economic evaluation of sotatercept add-on therapy
This cost-consequence analysis showed that the introduction of sotatercept as an add-on therapy for the treatment of patients with PAH in Italy has the potential to reduce mortality, hospitalizations and lung/heart transplants, thereby substantially reducing PAH disease management costs.
Authors
- Danilo Di Laura (ORCID: https://orcid.org/0000-0001-5204-5364)
- M. Jootun (ORCID: https://orcid.org/0009-0006-1629-1991)
- Gijs van de Wetering (ORCID: https://orcid.org/0009-0001-6498-2950)
- Rosita van den Puttelaar (ORCID: https://orcid.org/0000-0003-2216-6557)
- Andrea Marcellusi (ORCID: https://orcid.org/0000-0002-3974-3798)
- Martina Paoletti (ORCID: https://orcid.org/0000-0002-2564-6698)
Institutions
- University of Rome Tor Vergata (IT)
- MSD (UK) Limited (United Kingdom) (GB)
- MSD (Italy) (IT)
- Open University of the Netherlands (NL)
- University of Colombo (LK)
Publication Details
- Journal
- Journal of Medical Economics
- Published
- 2025-12-17
- DOI
- https://doi.org/10.1080/13696998.2025.2601456
- Citations
- 1
- Primary Topic
- Transplantation: Methods and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 2.01